Allow your patients benefit the advantages of IMMUNOSCORE®

Improve the clinical management with precision medicine

Discover the Decision Impact Program (DIP)

and measure the impact of IMMUNOSCORE® on your daily practice in localized colon cancer

International Clinical Studies demonstrate that after IMMUNOSCORE^® test result:

70%

stage II patients
in high risk group

might be spared adjuvant chemotherapy

50%

stage III patients

would benefit from adjustment of their treatment duration

Sign up for the Decision Impact Program - IMMUNOSCORE® in localized colon cancer

DIP program is a commercial offer that will allow you to:

- Improve your precision oncology practice

- Corroborate the clinical data with IMMUNOSCORE® test in your own experience.

- Estimate the overall cost savings and medico-economic impact with optimized use of therapeutic.

- Improve patient’s quality of life.

- Enhance personalized approach with innovative precision oncology tool.

This program will generate real-world evidence to sustain precision medicine implementation in your center.

IMMUNOSCORE® identifies Stage III colon cancer patient who may benefit from 6 months chemotherapy

IMMUNOSCORE® identifies Stage II colon cancer patients who might be spared from chemotherapy

To find out more about the Decision Impact Program and be contacted, please fill the form

Would you also be interested in our "Innovation Access Program" for locally advanced Rectal cancer?